Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer [0.03%]
转录标志指示RB功能与子宫内膜癌对CDK4/6抑制的反应相关性
Zelei Yang,Upendra Raj Bhattarai,Martin K Hayes et al.
Zelei Yang et al.
Purpose: CDK4/6 inhibitors (CDK4/6is) are being investigated in endometrial cancer (EC) clinical trials with some patients showing a significant response. However, there are few biomarkers to predict which EC patients wil...
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal? [0.03%]
从细胞凋亡恢复药物Xevinapant的视角看“SMAC”下调:它的故事揭示了什么?
Pablo Jimenez-Labaig,Oriol Mirallas,Charleen Chan Wah Hak et al.
Pablo Jimenez-Labaig et al.
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAPs) from the SMAC-mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and pr...
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388) [0.03%]
曲普替尼联合[177Lu]镥-多妥泰治疗神经内分泌肿瘤患者的I期多中心研究(ETCTN 10388)
Aman Chauhan,Heidi L Weiss,Charles Kunos et al.
Aman Chauhan et al.
Introduction: Next generation of Theranostics studies are looking at novel combinations with radiation sensitizers to enhance PRRT's efficacy. Here, we present safety and efficacy data from a multi-center phase 1 study of...
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer [0.03%]
非小细胞肺癌患者中CDKN2A/MTAP缺失的基因组景观及其与治疗结果的相关性
Natalie I Vokes,Jessica L Symons,Brooke Rhead et al.
Natalie I Vokes et al.
Introduction: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NS...
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial [0.03%]
耐昔妥珠单抗联合派姆单抗治疗≥50%PD-L1表达的晚期非小细胞肺癌患者疗效和安全性:一项非随机Ⅱ期临床试验
Atsushi Horiike,Hiroshi Wakui,Shunichi Sugawara et al.
Atsushi Horiike et al.
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1)...
Preclinical characterization of CLSP-1025, a first-in-class, mutation-specific T-cell engager targeting a neoantigen derived from a common p53 mutation [0.03%]
靶向常见p53突变衍生neo抗原的首创新药CLSP-1025(TCE)的临床前研究
Michael F Maloney,Justina X Caushi,Lenore A Cullen et al.
Michael F Maloney et al.
Purpose: Targeting intracellular oncogenic mutations with T-cell engagers has the potential to expand precision immunotherapy beyond surface antigens. Here, we describe the preclinical characterization of CLSP-1025, a mut...
First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma [0.03%]
[211At].meta-碘苯基氮杂二环庚烷治疗肾上腺嗜铬细胞瘤或副神经瘤的首次人体、开放性、单臂Ⅰ期临床研究
Shozo Okamoto,Kaori Nomura,Tohru Shiga et al.
Shozo Okamoto et al.
Purpose: The efficacy of current therapeutic options for pheochromocytomas and paragangliomas, such as 131I-meta-iodobenzylguanidine (131I-MIBG), is limited owing to low complete response rates and a requirement for prolo...
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial [0.03%]
塞雷昔单抗联合贝伐珠单抗和化疗治疗晚期结直肠腺癌二线疗法:II期DeFianCe试验
Zev A Wainberg,Keun-Wook Lee,Jong Gwang Kim et al.
Zev A Wainberg et al.
Purpose: DeFianCe was a randomized phase 2 study evaluating sirexatamab, a Dickkopf-related protein 1 (DKK1)-neutralizing antibody, plus chemotherapy and bevacizumab as second-line therapy for metastatic colorectal cancer...
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study [0.03%]
基于陆地标志的ctDNA分子反应代表了肺癌免疫治疗结果的早期预测因素:临床验证研究
Noushin Niknafs,Lavanya Sivapalan,Archana Balan et al.
Noushin Niknafs et al.
Purpose: Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non-small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response requi...
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial [0.03%]
他尼戈替尼治疗晚期实体瘤的多激酶抑制作用:一项国际多中心Ib/II期临床试验的结果
Sarina A Piha-Paul,Chih-Yi Liao,Farshid Dayyani et al.
Sarina A Piha-Paul et al.
Purpose: Tinengotinib, a multikinase inhibitor targeting Aurora kinases A/B, fibroblast growth factor receptors (FGFRs) 1-3, vascular endothelial growth factor receptor-2, and Janus kinases 1-2, was evaluated in this phas...